HUTCHMED (CHINA) LIMIT

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

21 Nov 2024 23:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee 

20 Nov 2024 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

05 Nov 2024 23:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

31 Oct 2024 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

16 Oct 2024 00:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

24 Sep 2024 03:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

08 Sep 2024 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

30 Aug 2024 00:30:00 By Nasdaq GlobeNewswire

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

21 Aug 2024 04:30:00 By Nasdaq GlobeNewswire

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

31 Jul 2024 07:00:01 By Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

03 Jul 2024 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED to Announce 2024 Half-Year Financial Results

26 Jun 2024 04:30:00 By Nasdaq GlobeNewswire

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

24 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

21 Jun 2024 16:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

16 Jun 2024 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

06 Jun 2024 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

02 Jun 2024 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

23 May 2024 20:00:00 By Nasdaq GlobeNewswire

HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

17 May 2024 10:00:00 By Nasdaq GlobeNewswire

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

16 May 2024 20:00:00 By Nasdaq GlobeNewswire